Towards Healthcare
Antibiotic CDMO Market Set to Surge by 2034

Antibiotic CDMO Market 2025 Analysis Beta - Lactams Dominate, Sterile Injectables to Surge

The antibiotic CDMO market is growing because it provides services and support to antibiotic manufacturers from drug discovery to manufacturing, with comprehensive services. North America is dominant in the market due to advancements in manufacturing technologies and strong research infrastructure.

Content

  • Insight Code: 5991
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: August 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Shivani Zoting is a dedicated research analyst specializing in the healthcare industry. With a strong academic foundation, a B.Sc. in Biotechnology and an MBA in Pharmabiotechnology, she brings a unique blend of scientific understanding and market strategy to her research.

Shivani contributes to Towards Healthcare and plays an active role at Precedence Research, where she focuses on delivering in-depth market intelligence, competitive analysis, and trend forecasting across pharmaceuticals, medical devices, digital health, and healthcare services. Her insights support healthcare companies, investors, and policymakers in making data-backed decisions in a highly regulated and rapidly evolving sector.

Additionally, Shivani collaborates with Statifacts, further expanding her healthcare domain reach by engaging in diverse projects across global markets. Her strength lies in transforming complex clinical and commercial data into strategic narratives that help stakeholders navigate the future of healthcare.

Talk to us
FAQ's

The antibiotic CDMO market is projected to grow rapidly worldwide by 2034, driven by innovation, evolving needs, and rising healthcare demand.

North America is currently leading the antibiotic CDMO market due to cost-effective manufacturing and a large patient population.

The antibiotic CDMO market includes six segments such as by service type, by molecule type, by dosage form, by client type, by end-use application, and by region.

Some key players include Lonza Group, Catalent Inc., Thermo Fisher Scientific (Patheon), Cambrex Corporation, Curia Global, Inc., and Siegfried Holding AG.

Akums caters to the hundreds of pharma brands you see on pharmacy shelves in India. With 11 manufacturing plants and over 60 dosage forms, it one of the largest India-focused CDMOs.

Ministry of Health and Family Welfare, Government of India, National Institutes of Health, FDA, WHO, PIB, CDC.
Any Questions